Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07378943 · ClinicalTrials.gov registry record
A Study of Dosing Patterns and Costs in Patients With Spinal Muscular Atrophy Receiving Disease Modifying Therapies
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 4,114
- Enrollment target
NCT07378943: Completed study, sponsored by Novartis Pharmaceuticals.
NCT07378943 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 4,114 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07378943 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 4,114 participants
- Enrollment target
Study Summary
The aim of this study was to assess real-world dosing patterns, long-term healthcare costs, and characteristics of SMA patients who received treatment with DMTs. DMTs included onasemnogene abeparvovec, nusinersen, and risdiplam. This study was conducted using both open and closed claims data from the Komodo Health Research Database (KRD+) between 01 January 2016 and 31 October 2024.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,114 participants |
| Start Date | 2024-11-06 |
| Est. Completion | 2025-03-30 |
What the finished NCT07378943 record still lists
NCT07378943 is an observational study that tracks outcomes without assigning an intervention. Its 4,114 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT07378943 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07378943 about?
NCT07378943 is a clinical study titled "A Study of Dosing Patterns and Costs in Patients With Spinal Muscular Atrophy Receiving Disease Modifying Therapies". The aim of this study was to assess real-world dosing patterns, long-term healthcare costs, and characteristics of SMA patients who received treatment with DMTs. DMTs included onasemnogene abeparvovec, nusinersen, and risdiplam. This study was conducted using both open and closed claims data from th...
What is the current status of trial NCT07378943?
This trial is currently completed. The enrollment target is 4,114 participants. The study started on 2024-11-06. Estimated completion is 2025-03-30.
Who is sponsoring clinical trial NCT07378943?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03388606 · 4,100 participants
Characterization and Treatment of Adolescent Depression
- NCT06593353 · 4,165 participants · NA
Systems Analysis and Improvement to Optimize Opioid Use Disorder Care Quality and Continuity for Patients Exiting Jail
- NCT02693535 · 4,200 participants · Phase 2
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- NCT05969028 · 4,200 participants · NA
First Responder Airway & Compression Rate Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI